Cancer Immunotherapy and Experimental Therapeutics - T32

摘要 癌症仍然是美国发病率和死亡率的主要原因，这一发现是癌症研究的一个重大进展 以免疫为导向的疗法。这是一个快速变化的领域，需要未来的临床医生研究人员 基于与当前调查和实践截然不同的技能，因为宿主因素占据主导地位 而不是传统的解剖学驱动的参数。这个提议的T32计划的目标是培养未来 肿瘤学临床提供者和研究人员在最先进和最有前途的形式的免疫导向和 细胞疗法，通过将这些新需要的技能整合到满足这些独特需求的培训计划中。 新的挑战包括许多正在开发的新代理人，新的行动机制，一个独特的 毒性特征主要包括免疫/自身免疫副作用，以及缺乏患者选择或 这些疗法的预测性标记。机会是发明发展治疗学(DT) 最大限度地利用基于免疫的治疗的力量的策略。我们对提议的T32的愿景是 创建培训计划和环境，为临床实习生提供基本技能，同时 同时为他们提供了为发展下一代癌症做出贡献的机会 治疗。为了实施这一计划，我们将利用科学和翻译的优势 科罗拉多大学医学院。事实上，UCSOM有着深厚的基础历史 免疫研究(发现IL-1和刺痛)，以及过敏和自身免疫研究- 班级哮喘(全国犹太人)和糖尿病(芭芭拉·戴维斯)中心。UCSOM已提供2000万美元用于 发起人类免疫学和免疫疗法倡议(HI3)，并支持创建内部 生产临床级细胞治疗产品的设施，使CAR T细胞等尖端治疗成为可能。至 弥合了从板凳到床边的差距，人们投入了大量的努力来创造先进的、人性化的小鼠 模特们。此外，UCSOM是肿瘤学临床翻译的领导者，拥有享有盛誉的DT计划，以及 正是这种对早期DT的关注使我们成为免疫和细胞治疗的领导者。UCSOM有 创建了个性化医学中心，旨在促进寻求开发的科学/临床项目 针对患者的治疗方法。最后，将这些资源中的所有科学潜力与交付 在患者护理方面，医疗中心已投资5000多万美元，以增强支持数据的信息学能力 旨在优化临床决策和新疗法开发的挖掘和研究举措。这个 上述资源的总和为创建一个独特的培训方案奠定了基础，重点是 使临床研究人员和内科科学家为发现下一代免疫疗法做好准备。 这一计划将独特地量身定做，以适应临床研究员的特定培训要求，以 保证一流的研究培训，同时保持其核心临床经验的质量。这个 该计划将被指定为癌症免疫治疗和实验治疗计划(CIETP)。

ABSTRACT A significant advance in cancer, still a major cause of morbidity and mortality in the US, has been the discovery of immune-directed therapy. This is a rapidly changing field that will require future clinician researchers to draw upon a skillset that is quite distinct from current investigation and practice, as host factors take a dominant role over traditional, anatomical-driven parameters. The goal of this proposed T32 program is to train future oncology clinical providers and researchers in the most advanced and promising forms of immune-directed and cell therapy, by integrating those newly required skills into a training plan that addresses those unique needs. New challenges include a multitude of new agents under development, new mechanisms of action, a distinct toxicity profile mostly consisting of immune/autoimmune side effects, and the lack of patient selection or predictive markers for these therapies. The opportunity is to invent Developmental Therapeutics (DT) strategies that maximally exploit the power of immune-based therapy. Our vision for this proposed T32 is to create a training program and environment that will provide essential skills to clinical trainees while simultaneously providing them with the opportunity to contribute to developing the next generation of cancer therapies. To implement this program, we will draw upon the scientific and translational strengths of the University of Colorado School of Medicine (UCSOM). Indeed, the UCSOM has a strong history of basic immune research (discovery of IL-1 and STING), as well as allergy and autoimmunity research with world- class asthma (National Jewish), and diabetes (Barbara Davis) centers. The UCSOM has provided $20M to launch the Human Immunology and Immunotherapy Initiative (HI3), and has supported the creation of in-house facilities to produce clinical-grade cell therapy products, enabling cutting edge therapies like CAR T-cells. To bridge the bench-to-bedside gap, substantial efforts have been devoted to create advanced, humanized mouse models. Additionally, the UCSOM is a leader in oncology clinical translation with a prestigious DT program, and it was this focus in early DT that allowed us to become leaders in immune and cell therapy. The UCSOM has created a Personalized Medicine Center, designed to facilitate scientific/clinical programs seeking to develop patient-specific therapies. Finally, to link all of the scientific potential in these resources to the delivery of patient care, the medical center has invested over $50M to enhance informatics capabilities enabling data mining and research initiatives towards optimizing clinical decision-making and new therapy development. The sum of the resources outlined above provide the foundation for creating a unique training program, focused on preparing clinical investigators and physician scientists to discover the next generation of immunotherapies. This program will be uniquely tailored to adapt to the specific training requirements of clinical fellows, to guarantee top level research training while maintaining the quality of their core clinical experience. The program will be designated as the Cancer Immunotherapy and Experimental Therapeutics Program (CIETP).